TL;DR
This network meta-analysis evaluates the best non-invasive brain stimulation (rTMS) protocols for restoring leg function in stroke survivors. The study reveals a crucial "phase shift" in treatment efficacy: low-frequency stimulation (LFrTMS) is most effective within the first month post-stroke, while high-frequency stimulation (HFrTMS) becomes the superior choice for chronic recovery (>1 month).
What Problem Does This Paper Address?
Lower extremity motor dysfunction is a debilitating consequence of stroke, often leading to permanent disability and loss of independence. While repetitive transcranial magnetic stimulation (rTMS) has emerged as a powerful tool to induce neuroplasticity and aid recovery, the clinical landscape is cluttered with competing protocols.
Researchers and clinicians face a "paradox of choice": Should they use high or low frequency? Should they target the primary motor cortex (M1) or the cerebellum? Does the timing of the intervention—whether the patient is in the acute or chronic phase—change the outcome? Previous meta-analyses often lacked the granularity to compare multiple protocols simultaneously or failed to account for the "stroke phase," leaving the "optimal" protocol a matter of debate.
Methods
The authors performed a Network Meta-Analysis (NMA), a statistical technique that allows for the simultaneous comparison of multiple treatments, even if they haven't been compared directly in a single head-to-head trial.
They systematically reviewed 38 randomized controlled trials (RCTs) involving 2,022 patients. The study categorized interventions into five distinct rTMS protocols:
- HFrTMS-M1: High-frequency ($\ge$5Hz) stimulation of the ipsilateral (damaged) motor cortex.
- LFrTMS-M1: Low-frequency ($\le$1Hz) stimulation of the contralateral (healthy) motor cortex.
- iTBS-M1/Cerebellum: Intermittent Theta Burst Stimulation, a newer, faster mode of rTMS.
- dTMS-M1: Deep TMS, using specialized coils to reach deeper brain structures.
- Placebo: Sham stimulation.
The primary metric was the Fugl-Meyer Assessment of Lower Extremity (FMA-LE), supplemented by balance scales (BBS), mobility tests (TUGT), and physiological markers (MEP amplitude).
Datasets
The analysis drew from eight major databases (including PubMed, Embase, and CNKI) up to December 2023. While the studies spanned several countries (Korea, Italy, Egypt, India, Japan), the majority (28 out of 38) were conducted in China. This provides a robust dataset but suggests a potential geographic bias in the current body of evidence.
Key Insights and Ideas
- The Temporal Shift: The most significant finding is that the brain's response to rTMS changes over time. This supports the Interhemispheric Competition (IHC) model. Early on, the healthy hemisphere often over-inhibits the damaged one; LFrTMS helps by "quieting" that healthy side. Later, as the brain stabilizes, the damaged side needs a direct "boost" via HFrTMS.
- Targeting the Cerebellum: The study highlights the cerebellum as a viable alternative target. Specifically, iTBS-Cerebellum showed significant promise in improving balance (BBS), suggesting that motor recovery isn't just about the motor cortex—it's about the whole motor network.
- Efficiency vs. Efficacy: While newer protocols like iTBS are much faster to administer (minutes vs. half an hour), the data suggests that traditional rTMS protocols (HFrTMS and LFrTMS) currently have a stronger evidence base for efficacy in lower limb recovery.
Key Results
The researchers used SUCRA (Surface Under the Cumulative Ranking) values to rank the protocols (where 100% is the theoretical best):
- For General Motor Function (FMA-LE): LFrTMS-M1 ranked first overall (84.6%).
- Subgroup Analysis by Time:
- $\le$ 1 Month Post-Stroke: LFrTMS-M1 was the clear winner (98.9%).
- > 1 Month Post-Stroke: HFrTMS-M1 took the top spot (95.8%).
- For Balance and Physiology: HFrTMS-M1 was the most effective for the Berg Balance Scale (96.8%), the Timed Up and Go Test (80.3%), and increasing Motor Evoked Potential (MEP) amplitude (93.7%).
- For Walking Speed: LFrTMS-M1 was ranked as the most effective intervention (88.7%).
Limitations and Future Work
The authors acknowledge several hurdles:
- Heterogeneity: There was significant variation in "dosage"—the number of pulses, stimulation intensity, and total duration of treatment varied across the 38 studies.
- Data Scarcity for New Tech: Protocols like deep TMS (dTMS) and iTBS-M1 were represented by very few studies, making their rankings less stable.
- Reporting Gaps: Adverse events were not consistently reported, making it difficult to perform a rigorous safety comparison.
Future Direction: The field needs large-scale, multi-center RCTs that use standardized "doses" and provide long-term follow-up to see if these motor gains persist months after the stimulation ends.
Summary updated